Author Archives: Paul Samuel

NW Bio expands cancer drug study

Northwest Biotherapeutics Inc., of Bethesda, which is developing non-toxic personalized immune therapies for solid tumor cancers, said it completed recruiting patients for the first phase of a clinical trial testing the efficacy of a potential cancer drug.

Read More »

ImQuest gets FDA nod for clinical trial

ImQuest Pharmaceuticals, of Frederick, which develops novel therapeutic agents for the treatment of infectious diseases, and products for women’s health, said it received Food and Drug Administration approval for a clinical trial of a vaginal gel to prevent HIV transmission to women.

Read More »